Contract development and manufacturing organization (CDMO) Akums Group has announced a strategic long-term agreement valued at approximately €200 million (Rs 1,760 crore) with an undisclosed global pharmaceutical company. This collaboration will focus on the manufacturing and supply of oral liquid formulations for the European market.
Agreement Details and Financial Highlights
Under the terms of the agreement, Akums Group will produce multiple stock-keeping units (SKUs) of oral liquid formulations. These products will be marketed by the partner company across various European countries.
The deal includes an upfront payment of €100 million (Rs 880 crore) to Akums Group for product development and site approval from European regulatory authorities.
Expansion into Regulated Markets
Commenting on the partnership, Akums Managing Director Sanjeev Jain stated:
“This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.”
This agreement marks a significant step in Akums’ growth strategy, enabling the company to strengthen its presence in highly regulated international markets.
Production Timeline and Approval Milestones
The company will begin the commercial supply of oral liquid formulations in 2027 and will continue through 2032. As part of this initiative, Akums Group will initiate the European approval process for its oral liquid manufacturing facility.
The company expects to receive both site and product dossier approvals by the end of 2026. Akums already operates two European-approved facilities for injectables and oral solids, which it plans to leverage for this new venture.
A Strategic Leap for Akums
As reported by economictimes, this partnership underscores Akums’ capabilities as a trusted CDMO partner for global pharmaceutical companies. By combining its manufacturing expertise with European market approvals, Akums aims to solidify its position as a leader in the international pharmaceutical manufacturing sector.
